Full Press Release Details
Industry interviews
Nautilus Biotechnology
July 30, 2025
On this episode of Translating Proteomics , Parag, Andreas, and special guest Don Kirkpatrick answer questions submitted by the Translating Proteomics community. They cover:
• Needs in plasma proteomics
• How proteomics impacts drug development – with special guest Don Kirkpatrick Ph.D.!
• How lifestyle impacts the proteome
• How the Nautilus Proteome Analysis Platform is impacting tau and Alzheimer’s disease research
Stream this episode on YouTube , Apple Podcasts , or Spotify .
Chapters
00:00 – Intro 01:22 – Question 1 – What are we missing in plasma proteomics and do we need absolute plasma protein abundance? 10:11 – Question 2 – Can you provide examples of proteomics driving key clinical insights or drug development efforts? 26:31 – Question 3 – How does lifestyle impact the proteome? 34:44 – Question 4 – How does Nautilus’ technology create a unique breakthrough in terms of tau and Alzheimer’s disease? 45:16 – Outro
References
Shome et al., 2022 – Serum autoantibodyome reveals that healthy individuals share common autoantibodies https://www.sciencedirect.com/science/article/pii/S2211124722006489 LaBaer Lab paper investigating autoantibody levels in plasma and their relationship to health.
Sylman et al., 2018 – A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients https://www.nature.com/articles/s41598-018-25019-1 Mallick lab paper investigating temporal changes in platelets and their associations with cancer biology.
Krönke et al., 2014 – Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells https://www.science.org/doi/10.1126/science.1244851 Seminal paper describing selective protein degradation caused by lenalidomide.
Fink and Ebert 2015 – The novel mechanism of lenalidomide activity https://ashpublications.org/blood/article/126/21/2366/34644/The-novel-mechanism-of-lenalidomide-activity Review of research elucidating the mechanisms of lenalidomide activity
Ndoja et al., 2025 – COP1 Deficiency in BRAFV600E Melanomas Confers Resistance to Inhibitors of the MAPK Pathway https://www.mdpi.com/2073-4409/14/13/975 Describe links between kinase inhibitor vemurafenib and changes in ETV transcription factor degradation
Song et al., 2022 – RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy https://aacrjournals.org/cancerdiscovery/article/12/1/204/675622/RTK-Dependent-Inducible-Degradation-of-Mutant-PI3K Use proteomics to discover that inavolisib acts through selective degradation of mutant PI3Kα
Canon et al., 2019 – The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity https://www.nature.com/articles/s41586-019-1694-1 Covers the development of an inhibitor of KRAS mutant KRAS (G12C).
Schneider et al., 2024 – Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axis https://www.nature.com/articles/s42255-024-01108-6 Review on the gut-brain axis
Webpage for Johanna Lampe’s Lab at Fred Hutch Cancer Center https://www.fredhutch.org/en/faculty-lab-directory/lampe-johanna.html
Guseh et al., 2020 – An expanded repertoire of intensity-dependent exercise-responsive plasma proteins tied to loci of human disease risk https://www.nature.com/articles/s41598-020-67669-0 Work investigating the relationship between exercise, the plasma proteome, and health
Human Proteome Organization (HUPO) webpage with resources focused on proteomics in space https://hupo.org/Human-Proteomics-at-Extreme-Conditions
Joly et al., 2025 – Large-scale single-molecule analysis of tau proteoforms https://doi.org/10.1101/2025.06.26.660445 Nautilus preprint using Iterative Mapping of proteoforms to measure tau proteoforms in Alzheimer’s disease and related dementias samples.
Stream this episode on YouTube , Apple Podcasts , or Spotify .
Share this Article
Stay up-to-date on all things Nautilus
World-class articles, delivered weekly
MORE ARTICLES
Nautilus: Driving a revolution in proteomic analysis
New protein sequencing technology from Nautilus is unlocking the proteome and igniting a proteomics revolution.
Read more
Nautilus: Driving a revolution in proteomic analysis (Part 2)
We give you an inside view on how cross-disciplinary thinking and collaboration will propel us into a proteomics-powered future.
Read more
Interview with Andreas Huhmer – Senior Director of Scientific Affairs and Alliance Management
Andreas, Nautilus Senior Director of Alliance Management, describes why he’s excited to see researchers begin to use the Nautilus Platform.
Read more
Stay up-to-date on all things Nautilus